Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
نویسندگان
چکیده
Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells Marco Ruella, David M Barrett, Saad S Kenderian, Olga Shestova, Ted J Hofmann, John Scholler, Simon F Lacey, Jan J Melenhorst, Farzana Nazimuddin, Jessica Perazzelli, David A Christian, Christopher A Hunter, David L Porter, Carl H June, Stephan A Grupp, Saar Gill
منابع مشابه
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients. Developing approaches to preventing and treating a...
متن کاملCatch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Immunotherapy is the revolution in cancer treatment of this last decade. Among multiple approaches able to harness the power of the immune system against cancer, T cell based immunotherapies represent one of the most successful examples. In particular, biotechnological engineering of protein structures, like the T cell receptor or the immunoglobulins, allowed the generation of synthetic peptide...
متن کاملAdvancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects
Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...
متن کاملNovel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as CD19, CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results. Among...
متن کاملCAR-NK Cells: A Systematic Review of Emerging Alternative on Immunotherapy Against Leukemia
Background: Cancer is a public health emergency. It has a high mortality rate despite numerous studies on pharmaceutical therapies. Chimeric antigen receptor-natural killer (CAR-NK) cells are promising immunotherapy that could be used to treat cancer, especially leukemia. However, the evidence is still unclear. Thus, this systematic review aims to summarize the evidence regarding the use of CAR...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 3 شماره
صفحات -
تاریخ انتشار 2015